HDM2017 combination therapy for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new drug called HDM2017 in combination with other treatments for advanced colorectal cancer that cannot be removed by surgery or has spread. The goal is to see if this combination can help shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have advanced colorectal cancer that has spread or cannot be removed by surgery, confirmed by biopsy.
- You need to be in fairly good health, able to do daily activities (performance status 0 or 1).
- You must have at least one tumor that can be measured on scans.
- You must provide a tumor tissue sample (either from a previous biopsy or a new one).
- You have not been treated with certain types of chemotherapy called topoisomerase I inhibitors (like irinotecan) before.
- You are not pregnant or breastfeeding, and agree to use contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called HDM2017, which may help fight advanced colorectal cancer by targeting the CDH17 protein, combined with the usual treatments. It's for people whose cancer has spread and who haven't had certain prior treatments.
This trial tests a new drug called HDM2017 in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how it affects tumors.
This trial tests a new drug, MRG007, combined with other treatments for advanced colorectal cancer. The goal is to see if this combination can shrink tumors or slow the cancer's growth when standard treatments have not worked.
This trial tests a new targeted drug (SHR-A1811) combined with chemotherapy and bevacizumab versus the usual therapy for advanced colorectal cancer that hasn't been treated yet. It aims to see if the new combo works better as a first treatment.
This trial tests a new drug combined with standard chemotherapy and another medication for people with advanced colorectal cancer that has a specific genetic change (RAS mutation). It aims to see if the combination can help control the cancer better.
This trial tests a new drug (TQB2930) combined with chemotherapy, with or without another drug called bevacizumab, for people whose colorectal cancer has spread or cannot be removed by surgery and has a specific protein called HER2. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Hear when a new CRC, Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.